These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32931269)

  • 1. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
    Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
    J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
    Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
    Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
    Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
    Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
    Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
    ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
    Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
    ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
    Noce B; Di Bello E; Fioravanti R; Mai A
    Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
    Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
    Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances of LSD1/KDM1A inhibitors for disease therapy.
    Zhang C; Wang Z; Shi Y; Yu B; Song Y
    Bioorg Chem; 2023 May; 134():106443. PubMed ID: 36857932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
    Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
    Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
    Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
    Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity.
    Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ
    Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
    Baby S; Shinde SD; Kulkarni N; Sahu B
    ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.